Production & Sales

Dr. Reddy’s Laboratories sells antibiotic manufacturing site in Bristol, Tennessee

Dr. Reddy’s Laboratories has sold its antibiotic manufacturing facility and related assets in Bristol, Tennessee to Neopharma, a wholly owned subsidiary of the UAE’s largest pharmaceutical manufacturer headquartered in Abu Dhabi.

Recipharm acquires Sanofi inhalation contract manufacturing business

Recipharm has completed the purchase of Sanofi’s inhalation contract manufacturing business including a manufacturing plant situated in Holmes Chapel, UK.

Dova, Salix sign exclusive co-promotion deal for Doptelet

Dova Pharmaceuticals, Salix Pharmaceuticals and its parent company Bausch Health Companies have entered into an exclusive agreement to co-promote Dova’s Doptelet (avatrombopag) in the US.

Gilead to launch generic versions of hepatitis C drugs in US

Gilead Sciences is planning to launch authorized generic versions of Epclusa (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni (ledipasvir 90mg/sofosbuvir 400mg) in the US.

Tris Pharma acquires Pfizer’s subsidiary NextWave Pharmaceuticals

Tris Pharma, a developer of technology-based therapeutic products, has acquired Pfizer’s subsidiary NextWave Pharmaceuticals for an undisclosed sum.

Symbiosis gets FDA approval for manufacturing fill/finish process

Sterile manufacturing CDMO Symbiosis Pharmaceutical Services has secured approval from the US Food and Drug Administration (FDA) for its viral vector manufacturing fill/finish process at its biologics manufacturing facility in Scotland, UK.

Lonza adds two new Ibex solutions offerings to Swiss biopark

Swiss multinational, chemicals and biotechnology firm Lonza has added two new Ibex solutions offerings to its 100,000m² biopark in Visp, Switzerland.

Grifols secures FTC’s conditional approval for Biotest US acquisition

The US Federal Trade Commission (FTC) has approved a final order which requires Grifols to sell certain assets as a condition for its acquisition of Biotest US in accordance with the federal antitrust law.

Norgine to commercialize Shield’s iron deficiency therapy in Europe, Australia and New Zealand

Shield Therapeutics and Norgine have entered into an exclusive licence agreement in Europe, Australia and New Zealand, under which Norgine will commercialise Feraccru, Shield’s approved product for the treatment of iron deficiency in adults.